CA2495537A1 - Immunoregulatory compounds and derivatives and methods of treating diseases therewith - Google Patents
Immunoregulatory compounds and derivatives and methods of treating diseases therewith Download PDFInfo
- Publication number
- CA2495537A1 CA2495537A1 CA002495537A CA2495537A CA2495537A1 CA 2495537 A1 CA2495537 A1 CA 2495537A1 CA 002495537 A CA002495537 A CA 002495537A CA 2495537 A CA2495537 A CA 2495537A CA 2495537 A1 CA2495537 A1 CA 2495537A1
- Authority
- CA
- Canada
- Prior art keywords
- use according
- group
- compound
- hydrogen
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C245/00—Compounds containing chains of at least two nitrogen atoms with at least one nitrogen-to-nitrogen multiple bond
- C07C245/02—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides
- C07C245/06—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings
- C07C245/08—Azo compounds, i.e. compounds having the free valencies of —N=N— groups attached to different atoms, e.g. diazohydroxides with nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings with the two nitrogen atoms of azo groups bound to carbon atoms of six-membered aromatic rings, e.g. azobenzene
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Compounds are disclosed having the structure of Formula (I), where R1, R3, and R4 are independently hydrogen or C1 to C4 alkyl, and R2 is (II), where R5 is selected from the group consisting of hydrogen and C1 to C4 alkyl, or (III), where R6, R7 in R8 are independently hydrogen or C1 to C4 alkyl; or the esters or pharmacologically acceptable salts thereof. Such compounds may be utilized for the prophylaxis or treatment of various diseases, particularly inflammatory conditions of the GI tract. Methods of treating inflammatory conditions of the GI tract such as inflammatory bowel disease using compounds having the following formula are also disclosed (IV), where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl, and R12 is selected from the group consisting of hydrogen and -C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group.
Claims (17)
1. Use of a compound of Formula II:
where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl; and R12 is selected from the group consisting of hydrogen and -C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group;
or an ester or a pharmaceutically acceptable salt of such compound to treat an inflammatory condition of the gastrointestinal tract in a subject in need of such treatment.
where R9, R10 and R11 are independently selected from the group consisting of hydrogen and C1 to C4 alkyl; and R12 is selected from the group consisting of hydrogen and -C(O)R13, where R13 is a C1 to C6 alkyl or an aryl group;
or an ester or a pharmaceutically acceptable salt of such compound to treat an inflammatory condition of the gastrointestinal tract in a subject in need of such treatment.
2. The use according to Claim 1, wherein R9, R10, and R11 are independently selected from the group consisting of H, CH3, CH2CH3, and CH(CH3)2.
3. The use according to Claim 1, wherein R9, R10, and R11 are independently selected from the group consisting of H and CH3.
4. The use according to Claim 1, wherein R12 is hydrogen.
5. The use according to Claim 1, wherein the compound of Formula II is 4-aminophenylacetic acid.
6. The use according to any one of Claims 1 to 5, wherein the inflammatory condition of the gastrointestinal tract is ulcerative colitis.
7. The use according to any one of Claims 1 to 5, wherein the inflammatory condition of the gastrointestinal tract is Crohn's disease.
8. The use according to any one of Claims 1 to 7, wherein the compound is orally administrable.
9. The use according to any one of Claims 1 to 7, wherein the compound is rectally administrable.
10. The use according to any one of claims 1 to 9 wherein the compound is used in admixture with a pharmaceutical diluent or carrier.
11. Use of an active pharmaceutical ingredient comprising (a) at least one compound selected from the group consisting of 4-aminophenylacetic acid, an ester thereof and a pharmaceutically acceptable salt thereof and (b) at least one compound selected from the group consisting of 5-aminosalicylic acid, an ester thereof and a pharmaceutically acceptable salt thereof.
12. The use according to Claim 11, wherein the 4-aminophenylacetic acid or ester or salt thereof is from about 10 to about 90 weight percent of the active pharmaceutical ingredient.
13. The use according to Claim 11 wherein the molar ratio of the 4-aminophenylacetic acid to the 5-aminosalicylic acid is between about 1:10 and about 10:1.
14. The use according to any one of Claims 11 to 13, wherein the inflammatory condition of the gastrointestinal tract is ulcerative colitis.
15. The use according to any one of Claims 11 to 14, wherein the inflammatory condition of the gastrointestinal tract is Crohn's disease.
16. The use according to any one of Claims 11 to 15, wherein the active pharmaceutical ingredient is orally administrable.
17. The use according to any one of Claims 11 to 15, wherein the active pharmaceutical ingredient is rectally administrable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22868300P | 2000-08-29 | 2000-08-29 | |
US60/228,683 | 2000-08-29 | ||
CA002420576A CA2420576C (en) | 2000-08-29 | 2001-08-28 | Immunoregulatory compounds, derivatives thereof and their use |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002420576A Division CA2420576C (en) | 2000-08-29 | 2001-08-28 | Immunoregulatory compounds, derivatives thereof and their use |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2495537A1 true CA2495537A1 (en) | 2002-03-07 |
CA2495537C CA2495537C (en) | 2010-03-30 |
Family
ID=22858180
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002420576A Expired - Lifetime CA2420576C (en) | 2000-08-29 | 2001-08-28 | Immunoregulatory compounds, derivatives thereof and their use |
CA2495537A Expired - Lifetime CA2495537C (en) | 2000-08-29 | 2001-08-28 | Immunoregulatory compounds and derivatives and methods of treating diseases therewith |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002420576A Expired - Lifetime CA2420576C (en) | 2000-08-29 | 2001-08-28 | Immunoregulatory compounds, derivatives thereof and their use |
Country Status (16)
Country | Link |
---|---|
US (5) | US6583128B2 (en) |
EP (2) | EP1642885B1 (en) |
JP (1) | JP4163946B2 (en) |
AT (2) | ATE448194T1 (en) |
AU (3) | AU2001285311B2 (en) |
CA (2) | CA2420576C (en) |
CY (1) | CY1110593T1 (en) |
DE (2) | DE60140491D1 (en) |
DK (2) | DK1313697T3 (en) |
ES (2) | ES2333337T3 (en) |
HK (2) | HK1054221A1 (en) |
IL (3) | IL154536A0 (en) |
MX (1) | MXPA03001787A (en) |
PT (1) | PT1642885E (en) |
TW (1) | TWI249519B (en) |
WO (1) | WO2002018324A2 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1642885B1 (en) | 2000-08-29 | 2009-11-11 | Biocon Limited | Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract |
US8048924B2 (en) * | 2001-08-29 | 2011-11-01 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
CA2504287A1 (en) * | 2002-11-26 | 2004-06-10 | Nobex Corporation | Natriuretic compounds, conjugates, and uses thereof |
US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
US20060182692A1 (en) | 2003-12-16 | 2006-08-17 | Fishburn C S | Chemically modified small molecules |
KR101168620B1 (en) * | 2003-12-16 | 2012-08-03 | 넥타르 테라퓨틱스 | Pegylated small molecules |
US8198328B2 (en) * | 2004-01-21 | 2012-06-12 | New York University | Treatment of cancer using benzoic acid derivatives |
JP2007520495A (en) | 2004-02-06 | 2007-07-26 | ボロディー トーマス ユリウス | Use of aminosalicylic acid in diarrhea-type irritable bowel syndrome |
ES2687039T3 (en) * | 2004-03-23 | 2018-10-23 | Biocon Limited | Methods and compositions employing 4-aminophenylacetic acid compounds |
CN1988897B (en) * | 2004-05-28 | 2011-06-29 | 萨利克斯药物有限公司 | Use of balsalazide in preparing medicine for radiation induced enteritis |
US20080306029A1 (en) * | 2004-05-28 | 2008-12-11 | Salix Pharmaceuticals, Inc. | Prevention, Treatment, and Amelioration of Radiation Induced Enteritis |
US7932366B2 (en) * | 2004-07-07 | 2011-04-26 | Biocon Limited | Synthesis of azo bonded immunoregulatory compounds |
WO2006076471A2 (en) * | 2005-01-12 | 2006-07-20 | Nobex Corporation | Bnp conjugates and methods of use |
EP1688413A1 (en) * | 2005-02-03 | 2006-08-09 | Hikma Pharmaceuticals Co. Ltd. | Benzoxazole derivatives for the prophylaxis and treatment of inflammatory bowel diseases |
ITRM20050389A1 (en) | 2005-07-22 | 2007-01-23 | Giuliani Spa | COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS. |
ITRM20050390A1 (en) | 2005-07-22 | 2007-01-23 | Giuliani Spa | COMPOUNDS AND THEIR SPECIFIC SALTS FOR PPAR RECEPTORS AND RECEPTORS FOR EGF AND THEIR USE IN MEDICAL FIELDS. |
US8921344B2 (en) * | 2006-11-03 | 2014-12-30 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
US7452872B2 (en) * | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
CN102670626A (en) * | 2005-08-24 | 2012-09-19 | 萨利克斯药品公司 | Balsalazide formulations and manufacture and use thereof |
IE20070129A1 (en) * | 2007-02-28 | 2008-12-24 | Giuliani Int Ltd | Ppar-gamma agonists stimulate enteric defensin expression |
US7541384B2 (en) | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
US8436051B2 (en) * | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
US20090082314A1 (en) * | 2007-06-29 | 2009-03-26 | The Provost Fellows And Scholars Of The College Of The | Targeting Prodrugs for the Treatment of Gastrointestinal Diseases |
ITMI20072429A1 (en) * | 2007-12-24 | 2009-06-25 | Giuliani Int Ltd | COMPOUNDS FOR THE SELECTIVE TREATMENT OF THE INTESTINAL IMMUNE-INFLAMMATORY COMPONENT OF THE CELIAC DISEASE |
UA107562C2 (en) | 2008-12-05 | 2015-01-26 | METHOD OF TREATMENT OF PSORIASIS | |
JP5645851B2 (en) | 2009-02-16 | 2014-12-24 | ノグラ ファーマ リミテッド | How to treat hair-related conditions |
EA030762B1 (en) | 2012-02-09 | 2018-09-28 | Ногра Фарма Лимитед | Methods of treating fibrosis |
AU2013248397A1 (en) | 2012-04-18 | 2014-10-02 | Nogra Pharma Limited | Methods of treating lactose intolerance |
CN113825739A (en) | 2019-02-08 | 2021-12-21 | 诺格拉制药有限公司 | Process for preparing 3- (4' -aminophenyl) -2-methoxypropionic acid and analogs and intermediates thereof |
Family Cites Families (190)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1157169A (en) * | 1914-11-03 | 1915-10-19 | Geigy Ag J R | Mordant-dyeing azo dye. |
US2270676A (en) | 1936-08-20 | 1942-01-20 | Winthrop Chem Co Inc | Sulphonic acid amide compound |
US2314023A (en) | 1939-08-08 | 1943-03-16 | Chem Ind Basel | Substantive azo dyestuffs and process of making same |
US2336275A (en) | 1940-10-10 | 1943-12-07 | Eastman Kodak Co | Azo dye compound |
US2396019A (en) | 1943-02-05 | 1946-03-05 | Claude R Wickard | Insecticides |
NL301585A (en) | 1962-04-23 | |||
US3641040A (en) | 1968-03-27 | 1972-02-08 | Ciba Geigy Corp | Tertiary amino phenyl acetic acids |
FR2137211B1 (en) * | 1971-05-17 | 1974-08-02 | Bouchara Emile | |
BE791889A (en) | 1971-11-26 | 1973-05-24 | Pharmacia Ab | NEW DERIVATIVES OF PYRIDINE |
US4348399A (en) | 1978-02-02 | 1982-09-07 | American Cyanamid Company | Antiatherosclerotic and hypolipidemic 4-(monoalkylamino)phenyl alkane, alkene and alkyne carbinols, aldehydes, carboxylic acids and derivatives |
GR68102B (en) | 1978-08-08 | 1981-10-30 | Fujisawa Pharmaceutical Co | |
US4298595A (en) | 1978-12-20 | 1981-11-03 | Dynapol | Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract |
US4189607A (en) * | 1979-03-26 | 1980-02-19 | Taisho Pharmaceutical Co., Ltd. | Anilionotropone derivatives |
JPS57500432A (en) | 1980-03-20 | 1982-03-11 | ||
US4960765A (en) | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
SE8002321L (en) * | 1980-03-26 | 1981-09-27 | Pharmacia Ab | SETS AND INTERMEDIATES FOR PREPARING BENZOIC ACID DERIVATIVES |
SE8002322L (en) | 1980-03-26 | 1981-09-27 | Pharmacia Ab | Means for the treatment of inflammatory bowel diseases |
DE3027013A1 (en) | 1980-07-17 | 1982-02-18 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin | AGENTS FOR THE TREATMENT OF COLITIS ULCEROSA, ENTERITIS REGIONALIS CROHN (MORBUS CROHN), CHRONICALLY SPECIFIC COLITIS AND DIVERTICULITIS, AND USE OF SALICYLAZOBOZOIC ACID, FOR THE PRODUCTION OF SUCH A MEDIUM |
US4412992A (en) * | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
DE3047106A1 (en) * | 1980-12-13 | 1982-07-29 | Henkel Kgaa | TOPICAL COSMETIC PREPARATIONS FOR TREATING STRONG OILY HAIR AND SEBORRHEA SKIN |
US4374932A (en) | 1981-06-08 | 1983-02-22 | G. D. Searle & Co. | 5-ASA Drug delivery system |
ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
DE3151196A1 (en) | 1981-12-23 | 1983-06-30 | Kurt Heinz Prof. Dr. 7800 Freiburg Bauer | METHOD FOR PRODUCING EASILY SOLUBLE 5-AMINOSALICYL ACID MEDICAL PREPARATIONS |
FR2520233A1 (en) * | 1982-01-28 | 1983-07-29 | Oreal | COMPOSITION OF ANTHRALIN OR ONE OF ITS DERIVATIVES IN AN AROMATIC ESTER AND ITS USE IN THE TREATMENT OF SKIN DISEASES |
JPS58194814A (en) | 1982-05-11 | 1983-11-12 | Nippon Shinyaku Co Ltd | Drug having immunoregulating activity |
JPS59196839A (en) | 1983-04-21 | 1984-11-08 | Sankyo Co Ltd | Phenylacetic acid derivative |
SE8303399D0 (en) | 1983-06-15 | 1983-06-15 | Pharmacia Ab | AZO-BIS-SALICYL ACID AND SALT THEREOF, THEIR PHARMACEUTICAL PREPARATION AND PREPARATION OF THE ACID |
DE3323702A1 (en) | 1983-07-01 | 1985-01-10 | Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin | 5-AMINOSALICYL ACID-O-SULFATES OF PHYSIOLOGICALLY POSSIBLE BASES, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM |
US4539198A (en) | 1983-07-07 | 1985-09-03 | Rowell Laboratories, Inc. | Solid pharmaceutical formulations for slow, zero order release via controlled surface erosion: expanded range |
USRE33239E (en) | 1983-09-06 | 1990-06-26 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
US4664256A (en) | 1983-09-06 | 1987-05-12 | Farmaceutisk Laboratorium Ferring A/S | Packaged stable enema solution or suspension containing 5-aminosalicyclic acid |
US4657900A (en) | 1983-09-27 | 1987-04-14 | Rowell Laboratories | Pharmaceutical article of manufacture comprising a bisulfite stabilized aqueous solution of 5-aminosalicylic acid and method |
US4628083A (en) * | 1983-10-17 | 1986-12-09 | Pharmacia Ab | 2-hydroxy-5-(arylazo)-benzene alkanoic acids |
SE457505B (en) | 1984-01-10 | 1989-01-09 | Lejus Medical Ab | LAMINATED ORAL PHARMACEUTICAL COMPOSITION AND PROCEDURES FOR ITS PREPARATION |
US5137916A (en) * | 1985-11-14 | 1992-08-11 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
US5272176A (en) * | 1984-03-19 | 1993-12-21 | The Rockefeller University | Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use |
US5514676A (en) | 1984-03-19 | 1996-05-07 | The Rockefeller University | Amino-benzoic acids and derivatives, and methods of use |
US5476849A (en) | 1984-03-19 | 1995-12-19 | The Rockefeller University | Methods for glycosylation inhibition using amino-benzoic acids and derivatives |
US4663308A (en) | 1984-07-18 | 1987-05-05 | Medical College Of Ohio | Method of use of polymers containing cross-linked azo bonds for releasing therapeutic agents into the lower gastrointestinal tract |
DK153412C (en) | 1984-11-22 | 1988-12-19 | Ferring A S | PROCEDURE FOR THE PREPARATION OF P-AMINOPHENOLS BY ELECTROLYSE |
SE8405924L (en) | 1984-11-23 | 1986-05-24 | Pharmacia Ab | NEW AZO ASSOCIATIONS |
US4737240A (en) * | 1985-05-02 | 1988-04-12 | Ciba-Geigy Corporation | Trisazo black dyes from 2-(4'-aminophenylazo)-7-amino-1-naphthol-3-sulfonic acid |
ES8606254A1 (en) * | 1985-05-31 | 1986-04-01 | Lasa Lab | Prepn. of para -amino-benzoic acid derivs. |
JPS62240620A (en) | 1986-04-10 | 1987-10-21 | Hidekazu Masuhara | Sedative for toothache containing n-methacryloyl-aminosalicylic acid |
IN169307B (en) * | 1986-05-03 | 1991-09-28 | Hoechst Ag | |
SE462095B (en) | 1986-07-07 | 1990-05-07 | Nobel Kemi Ab | SAID TO MAKE 5-AMINOSALICYLIC ACID |
DE3627461A1 (en) * | 1986-08-13 | 1988-02-25 | Basf Ag | DYE MIXTURES |
US4999347A (en) * | 1986-08-28 | 1991-03-12 | Sorenson John R J | Analgesic method |
US4873321A (en) * | 1986-10-17 | 1989-10-10 | Sumitomo Chemical Company, Limited | Monazo compounds having a triozinyl bridging group and two vinylsulfone type fiber reactive groups |
US5026560A (en) | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
DE3889365D1 (en) * | 1987-03-13 | 1994-06-09 | Moeller Willi Ag | Adducts of keto compounds and anions of oxa acids, processes for their preparation, their use and azoketo compounds. |
AU1388388A (en) | 1987-04-01 | 1988-10-06 | Dak-Laboratoriet A/S | Benzoic acid derivatives and use thereof |
US5274002A (en) | 1987-04-14 | 1993-12-28 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
GB8709248D0 (en) | 1987-04-16 | 1987-05-20 | Wyeth John & Brother Ltd | Azo compounds |
US4849416A (en) | 1988-07-25 | 1989-07-18 | Rorer Pharmaceutical Corporation | Treatment of conditions requiring enhanced oxygen availability to mammalian tissues |
US5484605A (en) | 1988-11-25 | 1996-01-16 | Henning Berlin Gmbh Chemie-Und Pharmawerk | Agent for treating chronically inflammatory intestinal diseases |
EP0390499B2 (en) * | 1989-03-30 | 2000-02-16 | Ngk Insulators, Ltd. | Process for producing bismuth-based superconducting material |
GB8909559D0 (en) | 1989-04-26 | 1989-06-14 | Smith Kline French Lab | Pharmaceutical compositions |
US5010069A (en) | 1989-05-15 | 1991-04-23 | Marion Laboratories, Inc. | Stable liquid form of 5-aminosalicylic acid |
US5378470A (en) | 1989-07-25 | 1995-01-03 | Henning Berlin Gmbh | Rectally administered pharmaceutical preparation |
IT1246383B (en) | 1990-04-17 | 1994-11-18 | Eurand Int | METHOD FOR MASKING THE TASTE OF DRUGS |
US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
US5214191A (en) * | 1990-05-22 | 1993-05-25 | Cortech, Inc. | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase |
US5637618A (en) | 1990-06-01 | 1997-06-10 | Bioresearch, Inc. | Specific eatable taste modifiers |
US5629020A (en) | 1994-04-22 | 1997-05-13 | Emisphere Technologies, Inc. | Modified amino acids for drug delivery |
US5244922A (en) * | 1990-09-04 | 1993-09-14 | Burzynski Stanislaw R | Methods for treating viral infections |
US5254587A (en) | 1990-09-04 | 1993-10-19 | Burzynski Stanislaw R | Methods for treating AIDS |
US5519014A (en) * | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
GB9311281D0 (en) * | 1993-06-01 | 1993-07-21 | Rhone Poulenc Rorer Ltd | Novel composition of matter |
US5663208A (en) | 1991-03-01 | 1997-09-02 | Warner-Lambert Company | Antifungal wound healing compositions and methods for preparing and using same |
US5674912A (en) | 1991-03-01 | 1997-10-07 | Warner-Lambert Company | Sunscreen-wound healing compositions and methods for preparing and using same |
US5602183A (en) | 1991-03-01 | 1997-02-11 | Warner-Lambert Company | Dermatological wound healing compositions and methods for preparing and using same |
US5648380A (en) | 1991-03-01 | 1997-07-15 | Warner-Lambert Company | Anti-inflammatory wound healing compositions and methods for preparing and using same |
US5874479A (en) | 1991-03-01 | 1999-02-23 | Warner-Lambert Company | Therapeutic permeation enhanced-wound healing compositions and methods for preparing and using same |
IT1247884B (en) * | 1991-05-03 | 1995-01-05 | Gentili Ist Spa | ARYALKYL ESTERS OF THE ACID 4,5 DIHYDROXY-9,10-DIHYDRO-9,10-DIOXY 2-ANTHRACENCARBOXYL THERAPEUTIC ACTION |
GB9111426D0 (en) | 1991-05-28 | 1991-07-17 | Ici Plc | Chemical compounds |
US5502078A (en) | 1991-05-28 | 1996-03-26 | Zeneca Limited | Chemical compounds |
CA2110376C (en) | 1991-06-07 | 2003-02-11 | Adrianus J. Wittebrood | Pharmaceutical enema preparation |
US5629012A (en) | 1991-06-17 | 1997-05-13 | Farmaceutisk Laboratorium Ferring A/S | Process for producing suppositories by compression and suppositories obtained by the process |
DE4121849A1 (en) * | 1991-07-02 | 1993-01-14 | Rhone Poulenc Rorer Gmbh | New 4-(omega-arylalkyl)phenylalkanoic acid derivs. - used as LTB4 inhibitors for treating eczema, psoriasis, acne, arthritis, asthma, allergies or inflammatory bowel disease |
US5605930A (en) | 1991-10-21 | 1997-02-25 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for treating and preventing pathologies including cancer |
US5635532A (en) * | 1991-10-21 | 1997-06-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia |
US6037376A (en) | 1991-10-21 | 2000-03-14 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for therapy of cancer |
US5646182A (en) * | 1992-06-15 | 1997-07-08 | Burzynski; Stanislaw R. | Methods for treating autoimmune diseases |
US20050090553A1 (en) * | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
ATE214608T1 (en) * | 1992-06-30 | 2002-04-15 | Howard K Shapiro | USE OF A COMBINATION CONSISTING OF AN AMINO DERIVATIVE OR AMINE RELATED DERIVATIVE OF BENZOIC ACID AND AN AMINO-POLYSACCHARIDE FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT OF INFLAMMATORY DISEASES |
US6444221B1 (en) * | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
US5817321A (en) | 1992-10-08 | 1998-10-06 | Supratek Pharma, Inc. | Biological agent compositions |
US6008250A (en) * | 1993-05-26 | 1999-12-28 | Bioresearch, Inc. | Specific eatable taste modifiers |
DK66493D0 (en) | 1993-06-08 | 1993-06-08 | Ferring A S | PREPARATIONS FOR USE IN TREATMENT OF INFLAMMATORY GAS DISORDERS OR TO IMPROVE IMPROVED HEALTH |
US5585391A (en) * | 1993-10-08 | 1996-12-17 | Fhj Scientific, Inc. | Hydroxyl ions as unique therapeutic agents and compounds that modulate these ions, compositions employing these agents, therapeutic methods for using such agents and processes for preparing them |
DE4334678A1 (en) * | 1993-10-12 | 1995-04-13 | Basf Ag | Method for the detection of labeled mineral oils and new azo dyes |
DE4335496A1 (en) * | 1993-10-19 | 1995-04-20 | Basf Ag | Diphenylamine compounds |
FR2713486B1 (en) | 1993-12-14 | 1996-02-09 | Scophysa | New compositions for foams, in particular rectal foams, and foams thus obtained. |
DE4343823A1 (en) * | 1993-12-22 | 1995-06-29 | Basf Ag | Use of azo dyes for marking hydrocarbons as well as new azo dyes |
US5498608A (en) | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
GB9400972D0 (en) * | 1994-01-19 | 1994-03-16 | Zeneca Ltd | Process |
US5391575A (en) * | 1994-05-04 | 1995-02-21 | Burzynski; Stanislaw R. | Method for treating neurofibromatosis |
DE69512232T2 (en) * | 1994-05-10 | 2000-02-24 | Nicox Sa | NITRO CONNECTIONS AND THEIR PREPARATIONS WITH ANTI-FLAMMING, PAINT RELEASING AND ANTITHROMBOTIC EFFECTS |
AU698881B2 (en) * | 1994-05-11 | 1998-11-12 | Howard K. Shapiro | Compositions for treatment of chronic inflammatory diseases |
US6245774B1 (en) * | 1994-06-21 | 2001-06-12 | Celltech Therapeutics Limited | Tri-substituted phenyl or pyridine derivatives |
FR2726468B1 (en) * | 1994-11-03 | 1996-12-13 | Oreal | USE OF SALICYLIC ACID DERIVATIVE AS AN OIL-IN-WATER EMULSION STABILIZER |
US5905073A (en) | 1995-01-06 | 1999-05-18 | Salix Pharmaceuticals, Inc. | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
WO1996030003A1 (en) | 1995-03-30 | 1996-10-03 | Werner Kreutz | Medicaments for the selective treatment of tumour tissues |
US5703073A (en) | 1995-04-19 | 1997-12-30 | Nitromed, Inc. | Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs |
JP3964478B2 (en) * | 1995-06-30 | 2007-08-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Heterocycle-containing carboxylic acid derivative and pharmaceutical containing the same |
FR2738150B1 (en) | 1995-09-01 | 1997-10-31 | Synthelabo | USE OF SULPHASALAZINE AND ITS METABOLITES FOR THE MANUFACTURE OF A MEDICAMENT USEFUL IN THE TREATMENT OF VENOUS INSUFFICIENCY AND VENOUS ULCERS |
WO1997009329A1 (en) | 1995-09-08 | 1997-03-13 | J. Uriach & Cia. S.A. | Azo derivatives of 5-aminosalicylic acid for treatment of inflammatory bowel disease |
US6436969B1 (en) * | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
IT1277663B1 (en) | 1995-09-28 | 1997-11-11 | Crinos Industria Farmaco | STABLE AQUEOUS SUSPENSIONS OF MESALAZINE FOR TOPICAL USE |
US6008208A (en) * | 1995-10-23 | 1999-12-28 | Osteoscreen, Inc. | Compositions and methods for treating bone deficit conditions |
AU7664296A (en) * | 1995-11-02 | 1997-05-22 | Warner-Lambert Company | Naphthylazo inhibition of amyloidosis |
US5747532A (en) | 1995-11-21 | 1998-05-05 | Medinox, Inc. | Combinational therapeutic methods employing nitric oxide scavengers and compositions useful therefor |
GB9602444D0 (en) * | 1996-02-07 | 1996-04-03 | Chege Joseph | Pharmaceutical compositions for the prevention or treatment of retrovirus infections |
US6355680B1 (en) * | 1996-02-20 | 2002-03-12 | Exocell, Inc. | Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies |
CA2248549A1 (en) * | 1996-03-15 | 1997-09-18 | Munin Corporation | Extracellular matrix signalling molecules |
CA2249299C (en) | 1996-03-22 | 2004-02-17 | Mayo Foundation For Medical Education And Research | Combination of an ursodeoxycholic acid compound and a nsaid for the chemopreventive protection of the colorectum |
DE19621840A1 (en) * | 1996-05-31 | 1997-12-04 | Basf Ag | Process for the preparation of phenylazonaphthalenes |
KR20000022040A (en) | 1996-06-20 | 2000-04-25 | 보오드 오브 리젠츠, 더 유니버시티 오브 텍사스 시스템 | Compounds and methods for providing pharmacologically active preparations and uses thereof |
US5741896A (en) * | 1996-06-21 | 1998-04-21 | Allergan | O- or S- substituted tetrahydronaphthalene derivatives having retinoid and/or retinoid antagonist-like biological activity |
DE19627424A1 (en) | 1996-07-08 | 1998-01-15 | Bayer Ag | Process for the preparation of 4-hydroxyanilines |
US5935581A (en) * | 1996-07-24 | 1999-08-10 | Kapadia; Govind J. | Inhibitory effects of synthetic and natural colorants on carcinogenesis |
US5939456A (en) * | 1996-07-26 | 1999-08-17 | Perrine; Susan P. | Pulsed administration of compositions for the treatment of blood disorders |
US6245735B1 (en) | 1996-07-29 | 2001-06-12 | The Brigham And Women's Hospital, Inc. | Methods and products for treating pseudomonas infection |
US7030146B2 (en) * | 1996-09-10 | 2006-04-18 | University Of South Carolina | Methods for treating diabetic neuropathy |
US20030013746A1 (en) * | 1996-09-10 | 2003-01-16 | University Of Kansas Medical Center. | Advanced glycation end-product intermediaries and post-amadori inhibition |
CA2266404A1 (en) | 1996-09-17 | 1998-03-26 | Amur Pharmaceuticals, Inc. | Phospholipid drug derivatives |
KR100479314B1 (en) * | 1996-10-11 | 2006-03-23 | 가부시키가이샤 우에노 세이야꾸 오요 겡뀨조 | Naphthol derivative and process for preparing the same |
US5840966A (en) | 1996-10-17 | 1998-11-24 | Minister Of Health And Welfare | Hydroxylation of salicylic acid derivatives |
US5939455A (en) * | 1997-03-11 | 1999-08-17 | Beacon Laboratories, Inc. | Therapeutic augmentation of oxyalkylene diesters and butyric acid derivatives |
SE9700934D0 (en) * | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
US6551632B2 (en) * | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
NZ500696A (en) | 1997-04-01 | 2002-05-31 | Borody Thomas J | Methods and compositions for treating inflammatory bowel disease comprising mycobacterial agents, including macrolides |
AUPO665397A0 (en) | 1997-05-07 | 1997-05-29 | Borody, Thomas Julius | Novel therapy for constipation |
US5962710A (en) | 1997-05-09 | 1999-10-05 | Emisphere Technologies, Inc. | Method of preparing salicyloylamino acids |
KR20010013377A (en) * | 1997-06-04 | 2001-02-26 | 데이비드 엠 모이어 | Mild, leave-on antimicrobial compositions |
US6525038B1 (en) * | 1997-06-24 | 2003-02-25 | Werner Kreutz | Synergistic compositions for the selective control of tumor tissue |
DE19732903A1 (en) * | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet formulation for the treatment of the intestinal tract |
US6486214B1 (en) | 1997-09-10 | 2002-11-26 | Rutgers, The State University Of New Jersey | Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby |
US6281175B1 (en) | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
FR2772375B1 (en) * | 1997-12-15 | 2000-01-14 | Atochem Elf Sa | PROCESS FOR PACKAGING LONG CHAIN ALKYL ACRYLATES |
US6660283B2 (en) | 1997-12-19 | 2003-12-09 | Societe L'oreal S.A. | Use of cinnamic acid, or of at least one of its derivatives in a cosmetic composition |
FR2772612B1 (en) | 1997-12-19 | 2003-01-10 | Oreal | USE OF CINNAMIC ACID OR DERIVATIVES THEREOF IN A FIRMING COSMETIC COMPOSITION |
WO1999040883A2 (en) * | 1998-02-11 | 1999-08-19 | Faller Douglas V | Compositions and methods for the treatment of cystic fibrosis |
AU4154799A (en) * | 1998-06-02 | 1999-12-20 | Arthromics Plc | Compounds which interact with the thyroid hormone receptor for the treatment of fibrotic disease |
US6258849B1 (en) * | 1998-07-23 | 2001-07-10 | Stanislaw R. Burzynski | Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate |
KR20000011247A (en) | 1998-07-23 | 2000-02-25 | 김윤 | Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides |
IT1303672B1 (en) | 1998-07-28 | 2001-02-23 | Nicox Sa | NITRATED SALTS OF DRUGS ACTIVE IN BONE DISORDERS |
FR2782269B1 (en) * | 1998-08-17 | 2001-08-31 | Oreal | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION CONTAINING SALICYLIC ACID OR A SALICYLIC ACID DERIVATIVE AND USE THEREOF |
GB9818689D0 (en) * | 1998-08-28 | 1998-10-21 | Zeneca Ltd | Compounds |
CN1515547A (en) * | 1998-10-16 | 2004-07-28 | ��ʽ������Ұ��ҩӦ���о��� | Naphthol derivative |
IL126991A0 (en) | 1998-11-10 | 1999-09-22 | Yeda Res & Dev | Azobenzene derivatives and intermediates thereof |
ATE234090T1 (en) * | 1998-11-13 | 2003-03-15 | Lilly Co Eli | COMBINATION OF DULOXETINE WITH NON-STEROID ANTI-INFLAMMATORY DRUGS FOR THE TREATMENT OF PAIN |
DE19858997A1 (en) * | 1998-12-21 | 2000-06-29 | Dystar Textilfarben Gmbh & Co | Thermal migration-compatible azo dyes |
US6207700B1 (en) * | 1999-01-07 | 2001-03-27 | Vanderbilt University | Amide derivatives for antiangiogenic and/or antitumorigenic use |
US6326364B1 (en) * | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
US6589944B1 (en) | 1999-04-05 | 2003-07-08 | City Of Hope | Breakers of advanced glycation endproducts |
US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6423696B1 (en) | 1999-04-16 | 2002-07-23 | The United States Of America, As Represented By The Department Of Health & Human Services | Inhibition of arylamine N-acetyl transferase |
DE50001030D1 (en) | 1999-05-10 | 2003-02-13 | Ciba Sc Holding Ag | Azo dyes, processes for their preparation and their use for dyeing or printing natural or synthetic materials |
US6200964B1 (en) * | 1999-05-28 | 2001-03-13 | Neutrogena Corporation | Silicone gel containing salicylic acid |
US6403646B1 (en) * | 1999-06-30 | 2002-06-11 | David H. Perlmutter | Method for the treatment of alpha-1-antitrypsin deficiency and related pathologies |
US6653352B2 (en) | 1999-09-29 | 2003-11-25 | Medical Merchandising, Inc. | Pain reliever and method of use |
US6531291B1 (en) * | 1999-11-10 | 2003-03-11 | The Trustees Of Columbia University In The City Of New York | Antimicrobial activity of gemfibrozil and related compounds and derivatives and metabolites thereof |
JP4168557B2 (en) | 1999-11-25 | 2008-10-22 | 三浦工業株式会社 | Hardness measuring indicator and hardness measuring method |
ES2287040T3 (en) * | 1999-12-06 | 2007-12-16 | Leo Pharma A/S | AMINOBENZOPENONES AS INHIBITORS OF IL-BETA AND TNF-ALFA. |
CA2393083C (en) * | 1999-12-23 | 2010-01-26 | Novartis Ag | Use of hypoglycemic agent for treating impaired glucose metabolism |
AU2001241632A1 (en) * | 2000-02-28 | 2001-09-12 | The Procter And Gamble Company | Acidic antimicrobial compositions for treating food and food contact surfaces and methods of use thereof |
US6887632B2 (en) * | 2000-03-30 | 2005-05-03 | Council Of Scientific And Industrial Research | Liquid crystalline polymer films of polymers having azobenzene mesogenic groups in cross linked network structures, process for the preparation thereof, polymers and novel monomers having azobenzene mesogens |
US20020120008A1 (en) * | 2000-06-29 | 2002-08-29 | Seymour Benzer | Life extension of drosophila by a drug treatment |
DE10032019A1 (en) * | 2000-07-01 | 2002-01-10 | Clariant Gmbh | Process for the preparation of disazo condensation pigments in microreactors |
US6566507B2 (en) | 2000-08-03 | 2003-05-20 | Ciba Specialty Chemicals Corporation | Processes for the preparation of benzotriazole UV absorbers |
US6375733B1 (en) * | 2000-08-28 | 2002-04-23 | Engelhard Corporation | Heat stable monoazo magenta pigment compositions |
US6380256B1 (en) | 2000-08-29 | 2002-04-30 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
ATE460394T1 (en) | 2000-08-29 | 2010-03-15 | Biocon Ltd | 5-ASA DERIVATIVES HAVING ANTI-INFLAMMATORY AND ANTIBIOTIC ACTION AND METHOD FOR TREATING DISEASES USING THESE DERIVATIVES |
US6313107B1 (en) * | 2000-08-29 | 2001-11-06 | Allergan Sales, Inc. | Methods of providing and using compounds having activity as inhibitors of cytochrome P450RAI |
EP1642885B1 (en) * | 2000-08-29 | 2009-11-11 | Biocon Limited | Use of a pharmaceutical composition containing a para-aminophenyl acetic acid derivative for treating inflammatory conditions of the gastrointestinal tract |
US6369261B1 (en) | 2000-08-29 | 2002-04-09 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6387951B1 (en) * | 2000-08-29 | 2002-05-14 | Allergan Sales, Inc. | Compounds having activity as inhibitors of cytochrome P450RAI |
US6387952B1 (en) | 2000-09-19 | 2002-05-14 | Arco Chemical Technology L.P. | Method of treating gastrointestinal disorders, particularly colitis |
US20020061339A1 (en) * | 2000-09-28 | 2002-05-23 | Martin Stogniew | Compositions and methods for use of extracts of rutaceae plants |
MXPA03008108A (en) * | 2001-03-07 | 2003-12-12 | Procter & Gamble | Topical composition comprising a functional aromatic derivative cosmetic bonding agent. |
US7238680B2 (en) | 2001-06-01 | 2007-07-03 | Rosen Steven E | Topical compositions for veterinary uses |
US6791788B2 (en) * | 2001-06-29 | 2004-09-14 | Storage Technology Corporation | Segmented power strip for an automated robotic device and method for joining same |
US6528076B2 (en) * | 2001-07-06 | 2003-03-04 | Magic Herb Corp. | Topical compositions and methods for treating pain |
US6479528B1 (en) * | 2001-07-31 | 2002-11-12 | Neuronautics, Inc. | Methods for inhibiting or reversing tau filament formation polymerization |
US7022333B2 (en) * | 2001-10-02 | 2006-04-04 | Kimberly-Clark Worldwide, Inc. | Inhibition of exoprotein production in non-absorbent articles uisng aromatic compositions |
CA2464531A1 (en) * | 2001-11-05 | 2003-05-15 | Brigham And Women's Hospital, Inc. | Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases |
EP1456165A1 (en) * | 2001-11-30 | 2004-09-15 | The Burnham Institute | Induction of apoptosis in cancer cells |
US6548776B1 (en) * | 2002-04-12 | 2003-04-15 | Jenn Feng Industrial Co., Ltd. | Safety device for on/off switch of an electric tool |
-
2001
- 2001-08-28 EP EP05024822A patent/EP1642885B1/en not_active Expired - Lifetime
- 2001-08-28 EP EP01964460A patent/EP1313697B1/en not_active Expired - Lifetime
- 2001-08-28 MX MXPA03001787A patent/MXPA03001787A/en active IP Right Grant
- 2001-08-28 PT PT05024822T patent/PT1642885E/en unknown
- 2001-08-28 DE DE60140491T patent/DE60140491D1/en not_active Expired - Lifetime
- 2001-08-28 DK DK01964460T patent/DK1313697T3/en active
- 2001-08-28 TW TW090121181A patent/TWI249519B/en not_active IP Right Cessation
- 2001-08-28 DK DK05024822T patent/DK1642885T3/en active
- 2001-08-28 CA CA002420576A patent/CA2420576C/en not_active Expired - Lifetime
- 2001-08-28 JP JP2002523442A patent/JP4163946B2/en not_active Expired - Fee Related
- 2001-08-28 AU AU2001285311A patent/AU2001285311B2/en not_active Ceased
- 2001-08-28 ES ES05024822T patent/ES2333337T3/en not_active Expired - Lifetime
- 2001-08-28 WO PCT/US2001/026697 patent/WO2002018324A2/en active Application Filing
- 2001-08-28 IL IL15453601A patent/IL154536A0/en unknown
- 2001-08-28 CA CA2495537A patent/CA2495537C/en not_active Expired - Lifetime
- 2001-08-28 AT AT05024822T patent/ATE448194T1/en active
- 2001-08-28 DE DE60115465T patent/DE60115465T2/en not_active Expired - Lifetime
- 2001-08-28 AT AT01964460T patent/ATE311358T1/en active
- 2001-08-28 ES ES01964460T patent/ES2254470T3/en not_active Expired - Lifetime
- 2001-08-28 AU AU8531101A patent/AU8531101A/en active Pending
- 2001-08-29 US US09/942,464 patent/US6583128B2/en not_active Expired - Lifetime
-
2003
- 2003-02-19 IL IL154536A patent/IL154536A/en not_active IP Right Cessation
- 2003-05-23 US US10/444,668 patent/US6903082B2/en not_active Expired - Lifetime
- 2003-08-29 HK HK03106194A patent/HK1054221A1/en not_active IP Right Cessation
-
2004
- 2004-10-18 US US10/967,736 patent/US7151095B2/en not_active Expired - Lifetime
-
2005
- 2005-06-03 US US11/144,093 patent/US7119119B2/en not_active Expired - Lifetime
- 2005-12-14 AU AU2005244526A patent/AU2005244526B2/en not_active Ceased
-
2006
- 2006-09-07 US US11/470,655 patent/US7425578B2/en not_active Expired - Lifetime
- 2006-10-05 HK HK06111008.1A patent/HK1089749A1/en not_active IP Right Cessation
-
2010
- 2010-01-04 CY CY20101100001T patent/CY1110593T1/en unknown
- 2010-04-28 IL IL205420A patent/IL205420A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2495537A1 (en) | Immunoregulatory compounds and derivatives and methods of treating diseases therewith | |
JP3231042B2 (en) | Nitrate ester of 2- (2,6-di-halo-phenylamino) phenylacetic acid derivative and method for producing the same | |
GB2048268A (en) | Amides of acyl-carnitines process for preparing same and pharmaceutical compositions containing such amides | |
CA2131683A1 (en) | Stilbene derivatives and pharmaceutical compositions containing them | |
CA2656415A1 (en) | Novel pyridazine compound and use thereof | |
CA2421114A1 (en) | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith | |
EP2684573A3 (en) | Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis | |
JP2004517813A5 (en) | ||
CA2643005A1 (en) | Imidazole-5-carboxylic acid derivatives,the preparation method therefor and the uses thereof | |
US4732916A (en) | Novel guanidinomethylbenzoic acid derivatives | |
TW470742B (en) | Benzimidazole derivatives, preparation and pharmaceutical compositions thereof | |
CA2210492A1 (en) | Neuraminic acid derivatives, their preparation and their medical use | |
CA2554070A1 (en) | Macrolides with antiinflammatory activity | |
CA2040319A1 (en) | Sulfonylamino substituted bicyclyl hydroxamic acid derivatives | |
CA2362211A1 (en) | Benzamide derivatives and medicament containing the same | |
US4824856A (en) | Method of protecting gastrointestinal tract | |
JP2008500314A5 (en) | ||
JP2589245B2 (en) | N- (3-alkyl (or alkenyl) -4-hydroxybenzoyl) glycine zinc complex | |
JPS6330462A (en) | Novel guanidinomethylbenzamide derivative and antiulcer agent containing said derivative as active ingredient | |
KR850001224B1 (en) | Process for preparing 2,4-dioxacyclohexanone derivatives | |
US3773712A (en) | Aminobenzoic acid derivatives | |
JPS5476532A (en) | Preparation of guanidino-fatty acid derivative | |
CA2526852A1 (en) | Use of 2h- [1,3] - oxazino [3,2-a] indole derivatives for the treatment of neuropathic pain | |
JPH0419967B2 (en) | ||
CA2355266A1 (en) | Process for producing salt of cyanobenzylamines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20210830 |